C12N 2800/108
Episomal vectors
Official title: episomal vectors
C12N2800/108 (Episomal vectors) appears on 414 US grants and 370 published applications in this corpus.
Search patents in C12N- Granted patents
- 414
- Published applications
- 370
- Assignees
- 269
- Inventors
- 897
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 10 | 0 |
| 1997 | 31 | 0 |
| 1998 | 40 | 0 |
| 1999 | 13 | 0 |
| 2000 | 25 | 0 |
| 2001 | 15 | 7 |
| 2002 | 23 | 26 |
| 2003 | 27 | 49 |
| 2004 | 10 | 32 |
| 2005 | 17 | 36 |
| 2006 | 11 | 26 |
| 2007 | 19 | 15 |
| 2008 | 14 | 19 |
| 2009 | 13 | 18 |
| 2010 | 13 | 17 |
| 2011 | 16 | 19 |
| 2012 | 15 | 14 |
| 2013 | 11 | 14 |
| 2014 | 13 | 9 |
| 2015 | 13 | 10 |
| 2016 | 10 | 6 |
| 2017 | 9 | 12 |
| 2018 | 5 | 7 |
| 2019 | 5 | 5 |
| 2020 | 3 | 7 |
| 2021 | 2 | 4 |
| 2022 | 2 | 7 |
| 2023 | 3 | 1 |
| 2024 | 1 | 2 |
| 2025 | 3 | 3 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Autologous cell replacement therapy for Parkinson's disease24 Mar 2026US 12,584,105 B2The McLean Hospital Corporation
- Platform for the induction and maintenance of ground state pluripotency8 Jul 2025US 12,351,831 B2Fate Therapeutics, Inc.
- Minimal volume reprogramming of mononuclear cells1 Apr 2025US 12,264,322 B2Fate Therapeutics, Inc.
- Non-integrating DNA vectors for the genetic modification of cells4 Feb 2025US 12,215,335 B2Deutsches Krebsforschungszentrum
- Selection method of iPS cell, preparation method of iPS cell, and control device20 Aug 2024US 12,065,675 B2Olympus Corporation
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
- Methods and compositions for targeted delivery of therapeutics11 Jun 2026US 2026/0158147 A1Manifold Biotechnologies, Inc.
- Method for reprogramming human somatic cells into induced pluripotent stem cells14 May 2026US 2026/0132384 A1Exoneuglia Biotechnology (Suzhou) Co., Ltd.
- Gene editing for controlled expression of episomal genes7 May 2026US 2026/0124230 A1Spark Therapeutics, Inc.
- Transposon system and methods of using the same19 Mar 2026US 2026/0078402 A1Upside Foods, Inc.
Most cited
By later US patents
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Preparation of functional human factor VIII in mammalian cells using methotrexate based selection276US 4,965,199 AGenentech, Inc. · 1990
- Production of erythropoietin237US 5,547,933 AKirin-Amgen, Inc. · 1996
- Production of recombinant erythropoietin199US 5,441,868 AKirin-Amgen, Inc. · 1995
- Deoxyribonucleic acid segment from a virus193US 4,968,615 ACiba-Geigy Corporation · 1990